{"schema_version":"1.0","type":"article","title":"Biotech 下一筆重磅併購，會落在誰身上？","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.md","lang":"zh-Hant","date":"2026-08-23","publish_at":"2026-08-23T08:00:00+08:00","updated_at":"2026-08-23","category":"商業分析系列","topic":"商業分析系列","tags":["生技併購","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","國邑","仁新","BD 授權"],"summary":"2026 年的生技併購資金，正集中到臨床風險開始下降、商業價值尚未完全定價的公司。從 Alkermes、Dyne、First Tracks、Legend 到 Sail，再回看國邑與仁新，真正值得追的是人體概念驗證、平台外延、商業化距離與買方策略契合度。","key_points":[],"facts":[],"sections":["01｜過去一年的交易，已經把新標準寫出來","02｜Orexin 升溫後，Alkermes 的位置變得更敏感","03｜Avidity 之後，Dyne 成為肌肉靶向核酸藥物最醒目的獨立標的","04｜CD122 變熱後，First Tracks 會被盯上","05｜Legend Biotech 的價值，已經不只 Carvykti","06｜Sail 已經被 J&J 提前卡位","07｜台灣誰符合「新併購語言」","結語｜下一筆重磅併購，會落在「風險剛下降」的公司身上","參考資料","免責聲明"],"references":[{"title":"[Novartis","source":"Successfully completes acquisition of Avidity Biosciences]","date":"","url":"https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy"},{"title":"[Gilead","source":"Completes acquisition of Arcellx ahead of potential commercial launch of anito-cel]","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Eli Lilly","source":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders]","date":"","url":"https://investor.lilly.com/node/54066"},{"title":"[Eli Lilly","source":"Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression]","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant"},{"title":"[argenx","source":"argenx to acquire Forte Biosciences, adding anti-CD122 antibody FB102]","date":"","url":"https://argenx.com/news/2026/press-release-3333257.html"},{"title":"[Alkermes","source":"Initiation of Phase 3 Brilliance studies evaluating alixorexton]","date":"","url":"https://investor.alkermes.com/node/23196/pdf"},{"title":"[Alkermes","source":"Detailed positive Vibrance-2 Phase 2 results]","date":"","url":"https://investor.alkermes.com/news-releases/news-release-details/alkermes-presents-detailed-positive-results-vibrance-2-phase-2/"},{"title":"[Dyne Therapeutics","source":"FDA accepts BLA for z-rostudirsen and grants Priority Review]","date":"","url":"https://www.dyne-tx.com/fda-accepts-bla-for-z-rostudirsen/"},{"title":"[First Tracks Biotherapeutics","source":"Second-quarter 2026 pipeline update]","date":"","url":"https://ir.firsttracksbio.com/news-releases/news-release-details/first-tracks-biotherapeutics-announces-second-quarter-2026"},{"title":"[First Tracks Biotherapeutics","source":"ANB033 overview]","date":"","url":"https://www.firsttracksbio.com/our-pipeline/anb033/overview/"},{"title":"[Legend Biotech","source":"First-quarter 2026 results and Carvykti sales]","date":"","url":"https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-reports-first-quarter-2026-results-and-recent/"},{"title":"[Legend Biotech","source":"LB2501 in vivo CD19/CD20 CAR-T Phase 1 data]","date":"","url":"https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-establishes-clinical-proof-concept-lb2501/"},{"title":"[Johnson & Johnson","source":"Strategic collaboration with Sail Biomedicines]","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Collaboration-with-Sail-Biomedicines-to-Advance-in-vivo-CAR-T-Programs-and-Transform-Autoimmune-Disease-Through-Immune-Reset/default.aspx"},{"title":"[ClinicalTrials.gov","source":"Re-Spire Phase 3 study of L606 in PH-ILD, NCT07285655]","date":"","url":"https://clinicaltrials.gov/study/NCT07285655"},{"title":"[Belite Bio","source":"Positive topline results from the Phase 3 DRAGON trial]","date":"","url":"https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite"},{"title":"[Belite Bio","source":"Completion of tinlarebant NDA rolling submission]","date":"","url":"https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us"},{"title":"查證截止日：2026 年 8 月 23 日。","source":"","date":"","url":""}],"images":[{"alt":"圖 1｜大型藥廠的新併購標準，落在人體概念驗證、平台外延、買方契合與尚未完全定價的交會處","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-01.png"},{"alt":"圖 2｜Alkermes 的 alixorexton 已進入全球 Phase 3，並從嗜睡症與特發性嗜睡症向更大的中樞神經市場延伸","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-02.png"},{"alt":"圖 3｜Avidity 與 Forte 交易後，Dyne 的肌肉靶向核酸遞送與 First Tracks 的 CD122 免疫調節成為下一波觀察重點","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-03.png"},{"alt":"圖 4｜Legend、Sail 與台灣國邑、仁新的案例，呈現成熟收入、下一代平台、提前卡位與後期專科資產的不同交易語言","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-23）。Biotech 下一筆重磅併購，會落在誰身上？。https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}